A topical, multi-mechanistic, fixed-dose combination therapy primarily indicated for the treatment of androgenetic alopecia (male and female pattern hair loss) and alopecia areata. Hydrocortisone provides anti-inflammatory and immunosuppressive action to reduce perifollicular inflammation. Minoxidil is a vasodilator and potassium channel opener that promotes hair growth by prolonging the anagen phase and increasing blood flow to follicles. Tretinoin enhances epidermal penetration of minoxidil, normalizes follicular keratinization, and may upregulate follicular sulfotransferase activity, potentially improving minoxidil's conversion to its active form.
Adult: Apply 1 mL of the solution twice daily (morning and evening) to the dry scalp in the affected area. Total daily dose should not exceed 2 mL.
Note: 1. Apply to clean, dry scalp. 2. Part hair to expose affected area. 3. Use the applicator dropper to measure 1 mL. 4. Apply directly to scalp (not hair) and gently massage with fingertips. 5. Wash hands thoroughly after application. 6. Allow solution to dry completely (15-30 minutes) before using other hair products or going to bed. 7. Avoid contact with eyes, mucous membranes, and broken skin.
The combination works synergistically. Minoxidil sulfate opens ATP-sensitive potassium channels in vascular smooth muscle and hair follicle cells, causing vasodilation and increased blood flow. It also upregulates VEGF, prolongs the anagen (growth) phase, and may have anti-androgenic effects. Tretinoin binds to retinoic acid receptors (RARs/RXRs), normalizing dysfunctional follicular epithelium, reducing follicular plugging, and enhancing minoxidil penetration. It may also upregulate follicular sulfotransferase enzymes, increasing local conversion of minoxidil to its active sulfate metabolite. Hydrocortisone binds to glucocorticoid receptors, inhibiting inflammatory cytokines (IL-1, TNF-α), reducing perifollicular lymphocytic infiltration and inflammation common in alopecia areata and androgenetic alopecia.
Pregnancy: CONTRANDICATED. Tretinoin is a retinoid with teratogenic potential (Pregnancy Category D as per some classifications, X for systemic use). Minoxidil is Pregnancy Category C. Topical absorption, though low, poses an unacceptable risk. Avoid use in women of childbearing potential unless highly effective contraception is used.
Driving: Caution advised. Minoxidil can cause dizziness, lightheadedness, or syncope, especially during initial therapy or if excessive dose is applied. Patients should not drive or operate machinery until they know how the medication affects them.
| Topical corticosteroids (potent, e.g., Clobetasol) | Increased risk of skin atrophy and systemic corticosteroid effects. | Major |
| Oral/Minoxidil tablets | Additive hypotensive and fluid-retaining effects. | Major |
| Antihypertensives (especially vasodilators like hydralazine) | Potentiated hypotension, dizziness, syncope. | Moderate |
| Topical retinoids (e.g., adapalene, isotretinoin gel) | Increased risk of severe local irritation, dryness, and dermatitis. | Moderate |
| Photosensitizing drugs (e.g., tetracyclines, fluoroquinolones) | Increased risk of photosensitivity reactions due to tretinoin. | Moderate |
| CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) | May increase systemic levels of hydrocortisone and tretinoin. | Moderate |
Same composition (Hydrocortisone (0.01% w/v) + Minoxidil (12.5% w/v) + Tretinoin (0.025% w/v)), different brands: